6,678 trials
Tinea Pedis · Tinea Cruris
Primary: Naftifine Hydrochloride Pharmacokinetics Variables, Single and Multiple Dose — 138262.2; 15890.1; 68634.2; 17213.9 h*pg/mL
Intubation Depth
Primary: Intubation Depth — 323.8; 238.3 cm
Ovarian Cancer
Primary: Increase in SGK1 mRNA Expression Level — 1.5; 6.1 fold change
HIV Infections
Primary: Safety — 22; 3; 0; 18 percentage of participants
Mental Competency · Urinary Bladder, Overactive · Cognitive Function
Primary: Hopkins Verbal Learning Test - Revised — 22.00; 24.38; 6.71; 7.83 units on a scale
Emphysema · Alpha 1-proteinase Inhibitor Deficiency
Primary: Rate of Change of Adjusted Lung Density — -1.632; -1.352; -1.627; -1.256 g/L per year — p== 0.752
Opioid-Related Disorders · Neuralgia
Primary: Consumption of Fentanyl — 41; 50; 58 mg
Hepatitis C, Chronic
Primary: Percentage of Participants Who Achieve Sustained Virologic Response Rate At 24 Weeks Post Completion of the Treatment — 80.9; 78.2; 81.0; 61.5 Percentage of participants
Anorexia Nervosa · Eating Disorders
Primary: Proportion of Patients Remaining in Study at 1 Year — 0.265; 0.315 proportion of participants — p=0.57
Depressive Disorder, Major
Primary: Change in Quality of Life Enjoyment and Satisfaction Questionnaire, Short Form (Q-LES-Q-SF) From Baseline up to Day 56 — 39.3; 9.6; 15.1; 19.0 Units on a scale
Acute Coronary Syndrome
Primary: Platelet-thrombus Formation in an ex Vivo Model of Thrombosis — 56.3; 35.2 percent change
Pain
Primary: Change in the Pain Intensity Score (0-10 NRS) From Visit 1 (Baseline) to 6weeks After Treatment. — -2.32; -2.75 Scores on a scale — p=0.2658
Multiple Actinic Keratoses
Primary: Histological Lesion Clearance — 61.5; 38.5 percentage of complete clearance — p=0.375
Asthma
Primary: Percentage of Participants Making at Least One Critical Error After the First Assessment of Metered Dose Inhaler (MDI) Technique on Day 14 — 14 Percentage of Participants
Rheumatoid Arthritis
Primary: Percentage of Participants Who Remained in Low Disease Activity (LDA) (Disease Activity Score in 28 Joints-erythrocyte Sedimentation Rate [DAS28-ESR] <3.2) at Week 52…